Sam van Bohemen, Founder & Biomedical Engineering PhD Candidate
Dr Andre Kyme, Biomedical Engineering Lecturer
Dr Philip Boughton, Principal Biomedical Engineer | Head GSI-Lab
Dr Jeff Rogers, Clinical Neuropsychologist
A/Prof Noel Young, Imaging
A/Prof Mark Latt, Geriatrician
Raena Greenbaum, Postgraduate Medicine Candidate
Chris Baxter, Intellectual Property & Commercialisation Expert
Dr Philip Boughton, Medtech Development Expert
Paul Cohen, Clinical & Regulatory Affairs Expert
Dr Eugene Salole, Market Access & HTA Expert
Stroke is a critical medical condition that is anticipated to increase in prevalence with aging populations. COVID-19 has recently been linked to severe ischemic strokes. Technology that can provide objective real-time insights to assist with timely interventions are being sought after to limit brain injury and death.
The proprietary nuroflux™ wearable system will non-invasively monitor brain perfusion alongside vital activity to assist specialists. The current gold-standard for objective brain perfusion analysis in stroke patients is CT perfusion imaging. Repeated CT perfusion imaging is limited due to the ionizing radiation exposure risk for patients. Furthermore CT imaging does not provide continuous monitoring. In the time periods between CT scans (including during trearment) there is no way to quantitatively monitor brain activity and perfusion.
nuroflux™ is being developed to provide continuous, realtime monitoring of stroke treatment, to detect signs of new stroke events and to monitor stroke rehabilitation.
There is also scope for the nuroflux™ to be used in pre-hospital settings to help diagnose and monitor stroke patients.
The recurrence of stroke is a stark possibility for stroke patients in the short and long term. nuroflux™ is being designed to be self-administered for remote monitoring outside the clinic for at-risk patients.